Experience with more than 100 total artificial heart implants
Objective The SynCardia Total Artificial Heart (SynCardia Systems Inc, Tucson, Ariz) has been used as a bridge to cardiac transplantation in 930 patients worldwide and in 101 patients in our program. Our experience with SynCardia Total Artificial Heart implantation documents its indications, safety,...
Gespeichert in:
| Veröffentlicht in: | The Journal of thoracic and cardiovascular surgery 2012-03, Vol.143 (3), p.727-734 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 734 |
|---|---|
| container_issue | 3 |
| container_start_page | 727 |
| container_title | The Journal of thoracic and cardiovascular surgery |
| container_volume | 143 |
| creator | Copeland, Jack G., MD Copeland, Hannah, MD Gustafson, Monica, MD Mineburg, Nicole, RN, CCTC Covington, Diane, RN Smith, Richard G., MSEE Friedman, Mark, MD |
| description | Objective The SynCardia Total Artificial Heart (SynCardia Systems Inc, Tucson, Ariz) has been used as a bridge to cardiac transplantation in 930 patients worldwide and in 101 patients in our program. Our experience with SynCardia Total Artificial Heart implantation documents its indications, safety, and efficacy. Methods Data regarding preoperative condition, mortality, and morbidity have been reviewed and analyzed. Results From January 1993 to December 2009, 101 patients had bridge to transplant procedures with the SynCardia Total Artificial Heart. Ninety-one percent of cases were Interagency Registry for Mechanically Assisted Circulatory Support profile 1, and the remaining 9% of cases were failing medical therapy on multiple inotropic medications. The mean support time was 87 days (median, 53 days; range, 1–441 days). Pump outputs during support were 7 to 9 L/min. Adverse events included strokes in 7.9% of cases and take-back for hemorrhage in 24.7% of cases. Survival to transplantation was 68.3%. Causes of death of 32 patients on device support included multiple organ failure (13), pulmonary failure (6), and neurologic injury (4). Survival after transplantation at 1, 5, and 10 years was 76.8%, 60.5%, and 41.2%, respectively. The longest-term survivor is currently alive 16.4 years postimplantation. Conclusions These patients were not candidates for left ventricular assist device therapy and were expected to die. The SynCardia Total Artificial Heart offers a real alternative for survival with a reasonable complication rate in appropriate candidates who otherwise might have been assigned to hospice care. |
| doi_str_mv | 10.1016/j.jtcvs.2011.12.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_922500297</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022522311013808</els_id><sourcerecordid>922500297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-e4c82beb2114c20e9b53b9d684c50e1a53937b314bb420ac6a432e02ecb173973</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7uzqLxCkL-Kp26pKfx5WWJZdFRY8qOAtJJkaJm1_jElmdf-96ZlRwYunJMX7vlV5SogXCAUC1m_6oo_2PhQEiAVSAUCPxAqha_K6rb4-FqtUobwikmfiPIQeABrA7qk4I6KyopJW4vLm546948ly9sPFbTbOnrO41VOGAFmcox4y7aPbOOvSdcvpkblxN-gphmfiyUYPgZ-fzgvx5fbm8_X7_O7juw_XV3e5Lds25lzalgwbQiwtAXemkqZb121pK2DUlexkYySWxpQE2ta6lMRAbA02smvkhXh9zN35-fueQ1SjC5aHNATP-6A6oip99qCUR6X1cwieN2rn3aj9g0JQCzbVqwM2tWBTSCr5kuvlKX9vRl7_8fzmlASvTgIdrB42Xk_Whb-6qkaoaWl_edRxonHv2KtgD3DXzrONaj27_wzy9h-_HdzkUstv_MChn_d-SqAVqpAM6tOy4WXBmBJlC638BXven0A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>922500297</pqid></control><display><type>article</type><title>Experience with more than 100 total artificial heart implants</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Copeland, Jack G., MD ; Copeland, Hannah, MD ; Gustafson, Monica, MD ; Mineburg, Nicole, RN, CCTC ; Covington, Diane, RN ; Smith, Richard G., MSEE ; Friedman, Mark, MD</creator><creatorcontrib>Copeland, Jack G., MD ; Copeland, Hannah, MD ; Gustafson, Monica, MD ; Mineburg, Nicole, RN, CCTC ; Covington, Diane, RN ; Smith, Richard G., MSEE ; Friedman, Mark, MD</creatorcontrib><description>Objective The SynCardia Total Artificial Heart (SynCardia Systems Inc, Tucson, Ariz) has been used as a bridge to cardiac transplantation in 930 patients worldwide and in 101 patients in our program. Our experience with SynCardia Total Artificial Heart implantation documents its indications, safety, and efficacy. Methods Data regarding preoperative condition, mortality, and morbidity have been reviewed and analyzed. Results From January 1993 to December 2009, 101 patients had bridge to transplant procedures with the SynCardia Total Artificial Heart. Ninety-one percent of cases were Interagency Registry for Mechanically Assisted Circulatory Support profile 1, and the remaining 9% of cases were failing medical therapy on multiple inotropic medications. The mean support time was 87 days (median, 53 days; range, 1–441 days). Pump outputs during support were 7 to 9 L/min. Adverse events included strokes in 7.9% of cases and take-back for hemorrhage in 24.7% of cases. Survival to transplantation was 68.3%. Causes of death of 32 patients on device support included multiple organ failure (13), pulmonary failure (6), and neurologic injury (4). Survival after transplantation at 1, 5, and 10 years was 76.8%, 60.5%, and 41.2%, respectively. The longest-term survivor is currently alive 16.4 years postimplantation. Conclusions These patients were not candidates for left ventricular assist device therapy and were expected to die. The SynCardia Total Artificial Heart offers a real alternative for survival with a reasonable complication rate in appropriate candidates who otherwise might have been assigned to hospice care.</description><identifier>ISSN: 0022-5223</identifier><identifier>EISSN: 1097-685X</identifier><identifier>DOI: 10.1016/j.jtcvs.2011.12.002</identifier><identifier>PMID: 22245242</identifier><identifier>CODEN: JTCSAQ</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Arizona ; Biological and medical sciences ; Cardiac Surgical Procedures - adverse effects ; Cardiac Surgical Procedures - instrumentation ; Cardiac Surgical Procedures - mortality ; Cardiology. Vascular system ; Cardiothoracic Surgery ; Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care ; Female ; Heart Failure - mortality ; Heart Failure - surgery ; Heart, Artificial ; Humans ; Intensive care medicine ; Male ; Medical sciences ; Middle Aged ; Patient Selection ; Pneumology ; Postoperative Complications - etiology ; Postoperative Complications - mortality ; Prosthesis Design ; Prosthesis Failure ; Prosthesis Implantation - adverse effects ; Prosthesis Implantation - instrumentation ; Prosthesis Implantation - mortality ; Registries ; Survival Rate ; Time Factors ; Treatment Outcome ; Young Adult</subject><ispartof>The Journal of thoracic and cardiovascular surgery, 2012-03, Vol.143 (3), p.727-734</ispartof><rights>The American Association for Thoracic Surgery</rights><rights>2012 The American Association for Thoracic Surgery</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-e4c82beb2114c20e9b53b9d684c50e1a53937b314bb420ac6a432e02ecb173973</citedby><cites>FETCH-LOGICAL-c488t-e4c82beb2114c20e9b53b9d684c50e1a53937b314bb420ac6a432e02ecb173973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022522311013808$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27902,27903,65308</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25610627$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22245242$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Copeland, Jack G., MD</creatorcontrib><creatorcontrib>Copeland, Hannah, MD</creatorcontrib><creatorcontrib>Gustafson, Monica, MD</creatorcontrib><creatorcontrib>Mineburg, Nicole, RN, CCTC</creatorcontrib><creatorcontrib>Covington, Diane, RN</creatorcontrib><creatorcontrib>Smith, Richard G., MSEE</creatorcontrib><creatorcontrib>Friedman, Mark, MD</creatorcontrib><title>Experience with more than 100 total artificial heart implants</title><title>The Journal of thoracic and cardiovascular surgery</title><addtitle>J Thorac Cardiovasc Surg</addtitle><description>Objective The SynCardia Total Artificial Heart (SynCardia Systems Inc, Tucson, Ariz) has been used as a bridge to cardiac transplantation in 930 patients worldwide and in 101 patients in our program. Our experience with SynCardia Total Artificial Heart implantation documents its indications, safety, and efficacy. Methods Data regarding preoperative condition, mortality, and morbidity have been reviewed and analyzed. Results From January 1993 to December 2009, 101 patients had bridge to transplant procedures with the SynCardia Total Artificial Heart. Ninety-one percent of cases were Interagency Registry for Mechanically Assisted Circulatory Support profile 1, and the remaining 9% of cases were failing medical therapy on multiple inotropic medications. The mean support time was 87 days (median, 53 days; range, 1–441 days). Pump outputs during support were 7 to 9 L/min. Adverse events included strokes in 7.9% of cases and take-back for hemorrhage in 24.7% of cases. Survival to transplantation was 68.3%. Causes of death of 32 patients on device support included multiple organ failure (13), pulmonary failure (6), and neurologic injury (4). Survival after transplantation at 1, 5, and 10 years was 76.8%, 60.5%, and 41.2%, respectively. The longest-term survivor is currently alive 16.4 years postimplantation. Conclusions These patients were not candidates for left ventricular assist device therapy and were expected to die. The SynCardia Total Artificial Heart offers a real alternative for survival with a reasonable complication rate in appropriate candidates who otherwise might have been assigned to hospice care.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Arizona</subject><subject>Biological and medical sciences</subject><subject>Cardiac Surgical Procedures - adverse effects</subject><subject>Cardiac Surgical Procedures - instrumentation</subject><subject>Cardiac Surgical Procedures - mortality</subject><subject>Cardiology. Vascular system</subject><subject>Cardiothoracic Surgery</subject><subject>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</subject><subject>Female</subject><subject>Heart Failure - mortality</subject><subject>Heart Failure - surgery</subject><subject>Heart, Artificial</subject><subject>Humans</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Patient Selection</subject><subject>Pneumology</subject><subject>Postoperative Complications - etiology</subject><subject>Postoperative Complications - mortality</subject><subject>Prosthesis Design</subject><subject>Prosthesis Failure</subject><subject>Prosthesis Implantation - adverse effects</subject><subject>Prosthesis Implantation - instrumentation</subject><subject>Prosthesis Implantation - mortality</subject><subject>Registries</subject><subject>Survival Rate</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0022-5223</issn><issn>1097-685X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2LFDEQhoMo7uzqLxCkL-Kp26pKfx5WWJZdFRY8qOAtJJkaJm1_jElmdf-96ZlRwYunJMX7vlV5SogXCAUC1m_6oo_2PhQEiAVSAUCPxAqha_K6rb4-FqtUobwikmfiPIQeABrA7qk4I6KyopJW4vLm546948ly9sPFbTbOnrO41VOGAFmcox4y7aPbOOvSdcvpkblxN-gphmfiyUYPgZ-fzgvx5fbm8_X7_O7juw_XV3e5Lds25lzalgwbQiwtAXemkqZb121pK2DUlexkYySWxpQE2ta6lMRAbA02smvkhXh9zN35-fueQ1SjC5aHNATP-6A6oip99qCUR6X1cwieN2rn3aj9g0JQCzbVqwM2tWBTSCr5kuvlKX9vRl7_8fzmlASvTgIdrB42Xk_Whb-6qkaoaWl_edRxonHv2KtgD3DXzrONaj27_wzy9h-_HdzkUstv_MChn_d-SqAVqpAM6tOy4WXBmBJlC638BXven0A</recordid><startdate>20120301</startdate><enddate>20120301</enddate><creator>Copeland, Jack G., MD</creator><creator>Copeland, Hannah, MD</creator><creator>Gustafson, Monica, MD</creator><creator>Mineburg, Nicole, RN, CCTC</creator><creator>Covington, Diane, RN</creator><creator>Smith, Richard G., MSEE</creator><creator>Friedman, Mark, MD</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120301</creationdate><title>Experience with more than 100 total artificial heart implants</title><author>Copeland, Jack G., MD ; Copeland, Hannah, MD ; Gustafson, Monica, MD ; Mineburg, Nicole, RN, CCTC ; Covington, Diane, RN ; Smith, Richard G., MSEE ; Friedman, Mark, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-e4c82beb2114c20e9b53b9d684c50e1a53937b314bb420ac6a432e02ecb173973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Arizona</topic><topic>Biological and medical sciences</topic><topic>Cardiac Surgical Procedures - adverse effects</topic><topic>Cardiac Surgical Procedures - instrumentation</topic><topic>Cardiac Surgical Procedures - mortality</topic><topic>Cardiology. Vascular system</topic><topic>Cardiothoracic Surgery</topic><topic>Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care</topic><topic>Female</topic><topic>Heart Failure - mortality</topic><topic>Heart Failure - surgery</topic><topic>Heart, Artificial</topic><topic>Humans</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Patient Selection</topic><topic>Pneumology</topic><topic>Postoperative Complications - etiology</topic><topic>Postoperative Complications - mortality</topic><topic>Prosthesis Design</topic><topic>Prosthesis Failure</topic><topic>Prosthesis Implantation - adverse effects</topic><topic>Prosthesis Implantation - instrumentation</topic><topic>Prosthesis Implantation - mortality</topic><topic>Registries</topic><topic>Survival Rate</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Copeland, Jack G., MD</creatorcontrib><creatorcontrib>Copeland, Hannah, MD</creatorcontrib><creatorcontrib>Gustafson, Monica, MD</creatorcontrib><creatorcontrib>Mineburg, Nicole, RN, CCTC</creatorcontrib><creatorcontrib>Covington, Diane, RN</creatorcontrib><creatorcontrib>Smith, Richard G., MSEE</creatorcontrib><creatorcontrib>Friedman, Mark, MD</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Copeland, Jack G., MD</au><au>Copeland, Hannah, MD</au><au>Gustafson, Monica, MD</au><au>Mineburg, Nicole, RN, CCTC</au><au>Covington, Diane, RN</au><au>Smith, Richard G., MSEE</au><au>Friedman, Mark, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Experience with more than 100 total artificial heart implants</atitle><jtitle>The Journal of thoracic and cardiovascular surgery</jtitle><addtitle>J Thorac Cardiovasc Surg</addtitle><date>2012-03-01</date><risdate>2012</risdate><volume>143</volume><issue>3</issue><spage>727</spage><epage>734</epage><pages>727-734</pages><issn>0022-5223</issn><eissn>1097-685X</eissn><coden>JTCSAQ</coden><abstract>Objective The SynCardia Total Artificial Heart (SynCardia Systems Inc, Tucson, Ariz) has been used as a bridge to cardiac transplantation in 930 patients worldwide and in 101 patients in our program. Our experience with SynCardia Total Artificial Heart implantation documents its indications, safety, and efficacy. Methods Data regarding preoperative condition, mortality, and morbidity have been reviewed and analyzed. Results From January 1993 to December 2009, 101 patients had bridge to transplant procedures with the SynCardia Total Artificial Heart. Ninety-one percent of cases were Interagency Registry for Mechanically Assisted Circulatory Support profile 1, and the remaining 9% of cases were failing medical therapy on multiple inotropic medications. The mean support time was 87 days (median, 53 days; range, 1–441 days). Pump outputs during support were 7 to 9 L/min. Adverse events included strokes in 7.9% of cases and take-back for hemorrhage in 24.7% of cases. Survival to transplantation was 68.3%. Causes of death of 32 patients on device support included multiple organ failure (13), pulmonary failure (6), and neurologic injury (4). Survival after transplantation at 1, 5, and 10 years was 76.8%, 60.5%, and 41.2%, respectively. The longest-term survivor is currently alive 16.4 years postimplantation. Conclusions These patients were not candidates for left ventricular assist device therapy and were expected to die. The SynCardia Total Artificial Heart offers a real alternative for survival with a reasonable complication rate in appropriate candidates who otherwise might have been assigned to hospice care.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>22245242</pmid><doi>10.1016/j.jtcvs.2011.12.002</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-5223 |
| ispartof | The Journal of thoracic and cardiovascular surgery, 2012-03, Vol.143 (3), p.727-734 |
| issn | 0022-5223 1097-685X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_922500297 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Adolescent Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Arizona Biological and medical sciences Cardiac Surgical Procedures - adverse effects Cardiac Surgical Procedures - instrumentation Cardiac Surgical Procedures - mortality Cardiology. Vascular system Cardiothoracic Surgery Emergency and intensive cardiocirculatory care. Cardiogenic shock. Coronary intensive care Female Heart Failure - mortality Heart Failure - surgery Heart, Artificial Humans Intensive care medicine Male Medical sciences Middle Aged Patient Selection Pneumology Postoperative Complications - etiology Postoperative Complications - mortality Prosthesis Design Prosthesis Failure Prosthesis Implantation - adverse effects Prosthesis Implantation - instrumentation Prosthesis Implantation - mortality Registries Survival Rate Time Factors Treatment Outcome Young Adult |
| title | Experience with more than 100 total artificial heart implants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T09%3A50%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Experience%20with%20more%20than%20100%20total%20artificial%20heart%20implants&rft.jtitle=The%20Journal%20of%20thoracic%20and%20cardiovascular%20surgery&rft.au=Copeland,%20Jack%20G.,%20MD&rft.date=2012-03-01&rft.volume=143&rft.issue=3&rft.spage=727&rft.epage=734&rft.pages=727-734&rft.issn=0022-5223&rft.eissn=1097-685X&rft.coden=JTCSAQ&rft_id=info:doi/10.1016/j.jtcvs.2011.12.002&rft_dat=%3Cproquest_cross%3E922500297%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=922500297&rft_id=info:pmid/22245242&rft_els_id=S0022522311013808&rfr_iscdi=true |